Drug intelligence / Profile preview

MLAB-002

Development stage: Preclinical
Lead developer: MLAB Biosciences
Modality: Antibody-Based Therapeutics

Overview

MLAB-002 is an investigational antibody drug developed by MLAB Biosciences. It is currently in preclinical development and is being studied primarily for the treatment of muscular dystrophies. The therapeutic focus also includes broader nervous system diseases, congenital disorders, and skin and musculoskeletal diseases. As of May 2025, there are no published details on its specific molecular target or mechanism of action[1].

Beyond the preview

Go deeper on MLAB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLAB-002.

Explore the full profile